WJ01075

WJ01075 is an oral small molecule drug candidate developed by Suzhou Junjing BioSciences for the treatment of advanced solid tumors. It functions as an inhibitor of exportin 1 (XPO1), a nuclear export protein. By binding to XPO1, WJ01075 blocks the XPO1-mediated nuclear export of cargo proteins, including tumor suppressor proteins and growth regulatory proteins, thereby potentially restoring their function and inhibiting tumor cell proliferation[1][2][3]. The drug has been evaluated in phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and antitumor activity in patients with advanced malignant solid tumors[2][3][8].

Other names

XPO1 inhibitor WJ01075XPO-1 inhibitor WJ01075XPO 1 inhibitor WJ01075